Business
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., March 24, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the fiscal year ended December 31, 2024.
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/916621eb8eeb0177f6b439f896cfed80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q.wXXcPt20ivEBxLD0mcog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/916621eb8eeb0177f6b439f896cfed80","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bOUrRULskBkKOIa5bptwCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/916621eb8eeb0177f6b439f896cfed80","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 24, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the fiscal year ended December 31, 2024.","length":373,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized. Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025. Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fourth quarter of 2025."","length":478,"tagName":"p"},{"type":"text","content":"Pivotal Phase 3 NEAT Clinical Trial","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrolled 61 participants to date in the company’s Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical ...